Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia 

  Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]